Is Taxotere a strong chemo drug?
Because Taxotere is a strong chemotherapy drug, its side effects tend to be more extreme than drugs that treat less serious issues such as high cholesterol or blood pressure. Doctors may lower the dose or prescribe drugs that reduce the risk of allergic reactions to deal with these types of side effects.
How do you administer Taxotere?
The recommended dose of TAXOTERE is 75 mg/m2 administered intravenously over 1 hour immediately followed by cisplatin 75 mg/m2 over 30–60 minutes every 3 weeks [see Dosage Adjustments During Treatment (2.7)].
How long is docetaxel infusion?
Each treatment takes about an hour and you have it once every 3 weeks.
How do you infuse docetaxel?
The recommended dose of docetaxel is 75 mg/m2 as a 1-hour infusion, followed by cisplatin 75 mg/m2, as a 1- to 3-hour infusion (both on day 1 only), followed by 5-fluorouracil 750 mg/m2 per day given as a 24-hour continuous infusion for 5 days, starting at the end of the cisplatin infusion.
Does hair grow back after Taxotere?
Taxotere Hair Loss Hair loss is a well-known outcome of chemotherapy treatment, but hair is normally expected to grow back within 3-6 months after stopping treatment.
How long is Taxotere given?
Health care providers administer Taxotere through an IV for one hour ever three weeks, according to the drug’s label. Depending on the type of cancer, this can continue for several cycles.
How often is Taxotere given?
The recommended dose of TAXOTERE is 75 mg/m2 administered intravenously over 1 hour immediately followed by cisplatin 75 mg/m2 over 30-60 minutes every 3 weeks [see Dosage Adjustments During Treatment].
Do you always lose your hair with docetaxel?
Docetaxel causes hair loss. Most people will lose all their hair, including eyebrows, eyelashes and body hair. You may begin to lose your hair about two weeks after the first treatment, but it can happen earlier.
How is docetaxel dosed?
Which is worse FEC or docetaxel?
There were 100 deaths in the FEC/docetaxel arm (10%), compared with 135 deaths (13.5%) in the FEC-only arm. The overall survival rate, therefore, was 90.7% vs 86.7% (P = . 017), representing a 23% relative risk reduction.